ATE377019T1 - Verbesserter entschützungsmethode für die synthese von oligomerverbindungen - Google Patents

Verbesserter entschützungsmethode für die synthese von oligomerverbindungen

Info

Publication number
ATE377019T1
ATE377019T1 AT99307066T AT99307066T ATE377019T1 AT E377019 T1 ATE377019 T1 AT E377019T1 AT 99307066 T AT99307066 T AT 99307066T AT 99307066 T AT99307066 T AT 99307066T AT E377019 T1 ATE377019 T1 AT E377019T1
Authority
AT
Austria
Prior art keywords
synthesis
deprotection method
oligomer compounds
improved
improved deprotection
Prior art date
Application number
AT99307066T
Other languages
English (en)
Inventor
Vasulinga T Ravikumar
Muthiah Manoharan
Daniel C Capaldi
Achim Krotz
Douglas L Cole
Andrei Guzaev
Original Assignee
Isis Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26816507&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE377019(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Isis Pharmaceuticals Inc filed Critical Isis Pharmaceuticals Inc
Application granted granted Critical
Publication of ATE377019T1 publication Critical patent/ATE377019T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Saccharide Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AT99307066T 1999-02-04 1999-09-06 Verbesserter entschützungsmethode für die synthese von oligomerverbindungen ATE377019T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11856499P 1999-02-04 1999-02-04
US09/288,679 US6465628B1 (en) 1999-02-04 1999-04-09 Process for the synthesis of oligomeric compounds

Publications (1)

Publication Number Publication Date
ATE377019T1 true ATE377019T1 (de) 2007-11-15

Family

ID=26816507

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99307066T ATE377019T1 (de) 1999-02-04 1999-09-06 Verbesserter entschützungsmethode für die synthese von oligomerverbindungen

Country Status (6)

Country Link
US (7) US6465628B1 (de)
EP (1) EP1028124B2 (de)
JP (1) JP2000226399A (de)
AT (1) ATE377019T1 (de)
DE (1) DE69937439T3 (de)
ES (1) ES2296372T5 (de)

Families Citing this family (245)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5898031A (en) 1996-06-06 1999-04-27 Isis Pharmaceuticals, Inc. Oligoribonucleotides for cleaving RNA
US9096636B2 (en) 1996-06-06 2015-08-04 Isis Pharmaceuticals, Inc. Chimeric oligomeric compounds and their use in gene modulation
US7812149B2 (en) 1996-06-06 2010-10-12 Isis Pharmaceuticals, Inc. 2′-Fluoro substituted oligomeric compounds and compositions for use in gene modulations
US6465628B1 (en) * 1999-02-04 2002-10-15 Isis Pharmaceuticals, Inc. Process for the synthesis of oligomeric compounds
US6887990B1 (en) * 1999-02-05 2005-05-03 Amersham Biosciences Corp Method for deprotecting oligonucleotides
US7098192B2 (en) 1999-04-08 2006-08-29 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of STAT3 expression
MXPA02012216A (es) * 2000-06-12 2004-08-19 Avecia Biotechnology Inc Desproteccion de oligonucleotidos sinteticos usando un secuestrante de acrilonitrilo.
US6768005B2 (en) 2000-12-20 2004-07-27 Avecia Limited Process
CA2714353A1 (en) * 2000-12-05 2002-06-13 Avecia Biotechnology Inc Process for the preparation of phosphorothioate oligonucleotides
US20020147331A1 (en) * 2001-02-02 2002-10-10 Guzaev Andrei P. Methods for synthesis of oligonucleotides
ATE312841T1 (de) 2001-03-08 2005-12-15 Applera Corp Verfahren zum entschützen von oligonukleotide
CA2504720C (en) 2002-11-05 2013-12-24 Isis Pharmaceuticals, Inc. Chimeric oligomeric compounds and their use in gene modulation
AU2003291755A1 (en) 2002-11-05 2004-06-07 Isis Pharmaceuticals, Inc. Oligomers comprising modified bases for binding cytosine and uracil or thymine and their use
WO2004065579A2 (en) * 2003-01-16 2004-08-05 Isis Pharmaceuticals, Inc. Modified oligonucleotides for use in gene modulation
JP4579911B2 (ja) 2003-06-03 2010-11-10 アイシス・ファーマシューティカルズ・インコーポレイテッド スルビビン発現の調節
US7683036B2 (en) 2003-07-31 2010-03-23 Regulus Therapeutics Inc. Oligomeric compounds and compositions for use in modulation of small non-coding RNAs
US8969314B2 (en) 2003-07-31 2015-03-03 Regulus Therapeutics, Inc. Methods for use in modulating miR-122a
US20050053981A1 (en) 2003-09-09 2005-03-10 Swayze Eric E. Gapped oligomeric compounds having linked bicyclic sugar moieties at the termini
CA2538252C (en) 2003-09-18 2014-02-25 Isis Pharmaceuticals, Inc. 4'-thionucleosides and oligomeric compounds
EP2708541B1 (de) 2003-11-13 2015-01-28 Isis Pharmaceuticals, Inc. 5,6-Dihydroxy-Isoindol-Derivate als Linker für Oligomer-Festphasensynthese
US8569474B2 (en) 2004-03-09 2013-10-29 Isis Pharmaceuticals, Inc. Double stranded constructs comprising one or more short strands hybridized to a longer strand
US8790919B2 (en) 2004-03-15 2014-07-29 Isis Pharmaceuticals, Inc. Compositions and methods for optimizing cleavage of RNA by RNase H
JP2007531794A (ja) 2004-04-05 2007-11-08 アルニラム ファーマスーティカルズ インコーポレイテッド オリゴヌクレオチドの合成および精製に使用する方法および反応試薬
US8394947B2 (en) 2004-06-03 2013-03-12 Isis Pharmaceuticals, Inc. Positionally modified siRNA constructs
HRP20171705T1 (hr) 2004-07-02 2017-12-15 Geron Corporation Sinteza zaštićenih 3’-amino-nukleozidnih monomera
WO2006011673A1 (ja) * 2004-07-30 2006-02-02 Reverse Proteomics Research Institute Co., Ltd. 光切断型リンカーを利用したリガンド固定化固相担体
US7427675B2 (en) * 2004-08-23 2008-09-23 Isis Pharmaceuticals, Inc. Compounds and methods for the characterization of oligonucleotides
US7884086B2 (en) 2004-09-08 2011-02-08 Isis Pharmaceuticals, Inc. Conjugates for use in hepatocyte free uptake assays
EP1931780B1 (de) 2005-08-29 2016-01-06 Regulus Therapeutics Inc. Antisense-verbindungen mit verbesserter anti-mikrorna-aktivität
AU2007211082B2 (en) 2006-01-27 2012-09-27 Isis Pharmaceuticals, Inc. Oligomeric compounds and compositions for the use in modulation of microRNAs
CA2715289C (en) 2008-02-11 2019-12-24 Rxi Pharmaceuticals Corporation Modified rnai polynucleotides and uses thereof
CA2721969C (en) * 2008-04-24 2016-06-07 Girindus America, Inc. Process for the manufacture of oligonucleotides
US8815818B2 (en) 2008-07-18 2014-08-26 Rxi Pharmaceuticals Corporation Phagocytic cell delivery of RNAI
EP2342340A1 (de) 2008-09-22 2011-07-13 Rxi Pharmaceuticals Corporation Rna-interferenz bei hautindikationen
WO2010059226A2 (en) 2008-11-19 2010-05-27 Rxi Pharmaceuticals Corporation Inhibition of map4k4 through rnai
US9745574B2 (en) 2009-02-04 2017-08-29 Rxi Pharmaceuticals Corporation RNA duplexes with single stranded phosphorothioate nucleotide regions for additional functionality
US8067526B2 (en) * 2009-03-27 2011-11-29 Nof Corporation Method for producing polyoxalkylene derivative
CN103200945B (zh) 2010-03-24 2016-07-06 雷克西制药公司 眼部症候中的rna干扰
RU2615143C2 (ru) 2010-03-24 2017-04-04 Адвирна Самодоставляющие PHKi соединения уменьшенного размера
EP3560503B1 (de) 2010-03-24 2021-11-17 Phio Pharmaceuticals Corp. Rna-interferenz bei dermalen und fibrotischen erkrankungen
EP2555778A4 (de) 2010-04-06 2014-05-21 Alnylam Pharmaceuticals Inc Zusammensetzungen und verfahren zur hemmung der cd274/pd-l1-genexpression
CA3102008A1 (en) 2010-06-02 2011-12-08 Alnylam Pharmaceuticals, Inc. Compositions and methods directed to treating liver fibrosis
WO2012059510A1 (en) 2010-11-02 2012-05-10 Girindus America, Inc. Back pressure control during solid-phase synthesis on polymeric supports
CA2817256A1 (en) 2010-11-12 2012-05-18 The General Hospital Corporation Polycomb-associated non-coding rnas
US9920317B2 (en) 2010-11-12 2018-03-20 The General Hospital Corporation Polycomb-associated non-coding RNAs
EP2649182A4 (de) 2010-12-10 2015-05-06 Alnylam Pharmaceuticals Inc Zusammensetzungen und verfahren zur erhöhung einer erythropoietin (epo)-herstellung
EP2648763A4 (de) 2010-12-10 2014-05-14 Alnylam Pharmaceuticals Inc Zusammensetzungen und verfahren zur expressionshemmung der gene klf-1 und bcl11a
PH12013501969B1 (en) 2011-03-29 2018-08-31 Alnylam Pharmaceuticals Inc Compositions and methods for inhibiting expression of tmprss6 gene
EP3460064B8 (de) 2011-04-03 2024-03-20 The General Hospital Corporation d/b/a Massachusetts General Hospital Effiziente in-vivo-proteinexpression mittels modifizierter rna (mod-rna)
EP2723758B1 (de) 2011-06-21 2018-06-20 Alnylam Pharmaceuticals, Inc. Angiopoietin-3 (angptl3)-irna-zusammensetzungen und verwendungsverfahren dafür
WO2012178033A2 (en) 2011-06-23 2012-12-27 Alnylam Pharmaceuticals, Inc. Serpina1 sirnas: compositions of matter and methods of treatment
EP2739735A2 (de) 2011-08-01 2014-06-11 Alnylam Pharmaceuticals, Inc. Verfahren zur verbesserung der erfolgsquote von hämatopoetischen stammzellentransplantaten
AU2012308320C1 (en) 2011-09-14 2018-08-23 Translate Bio Ma, Inc. Multimeric oligonucleotide compounds
WO2013059740A1 (en) 2011-10-21 2013-04-25 Foundation Medicine, Inc. Novel alk and ntrk1 fusion molecules and uses thereof
US9133461B2 (en) 2012-04-10 2015-09-15 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of the ALAS1 gene
US9127274B2 (en) 2012-04-26 2015-09-08 Alnylam Pharmaceuticals, Inc. Serpinc1 iRNA compositions and methods of use thereof
EA201492116A1 (ru) 2012-05-16 2015-05-29 Рана Терапьютикс, Инк. Композиции и способы для модулирования экспрессии mecp2
BR112014028631A2 (pt) 2012-05-16 2017-10-17 Rana Therapeutics Inc composições e métodos para modulação da expressão da família de genes da hemoglobina
US10837014B2 (en) 2012-05-16 2020-11-17 Translate Bio Ma, Inc. Compositions and methods for modulating SMN gene family expression
EA201492122A1 (ru) 2012-05-16 2015-10-30 Рана Терапьютикс, Инк. Композиции и способы для модулирования экспрессии utrn
SG11201407483YA (en) 2012-05-16 2014-12-30 Rana Therapeutics Inc Compositions and methods for modulating smn gene family expression
AU2013262699A1 (en) 2012-05-16 2015-01-22 Rana Therapeutics, Inc. Compositions and methods for modulating ATP2A2 expression
US20150247141A1 (en) 2012-09-14 2015-09-03 Rana Therapeutics, Inc. Multimeric oligonucleotide compounds
US11230589B2 (en) 2012-11-05 2022-01-25 Foundation Medicine, Inc. Fusion molecules and uses thereof
EP2914621B1 (de) 2012-11-05 2023-06-07 Foundation Medicine, Inc. Neuartige ntrk1-fusionsmoleküle und verwendungen davon
CA3150658A1 (en) 2013-01-18 2014-07-24 Foundation Medicine, Inc. Methods of treating cholangiocarcinoma
WO2014130922A1 (en) 2013-02-25 2014-08-28 Trustees Of Boston University Compositions and methods for treating fungal infections
IL288931B2 (en) 2013-03-14 2025-05-01 Alnylam Pharmaceuticals Inc Compositions comprising a complementary portion of C5 IRNA and methods of using them
EP4286517A3 (de) 2013-04-04 2024-03-13 President and Fellows of Harvard College Therapeutische verwendungen einer genomänderung mit crispr-/cas-systemen
EA038792B1 (ru) 2013-05-22 2021-10-20 Элнилэм Фармасьютикалз, Инк. КОМПОЗИЦИИ НА ОСНОВЕ RNAi Serpina1 И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
KR102234623B1 (ko) 2013-05-22 2021-04-02 알닐람 파마슈티칼스 인코포레이티드 Ｔｍｐｒｓｓ6 조성물 및 이의 사용 방법
EP3004396B1 (de) 2013-06-06 2019-10-16 The General Hospital Corporation Zusammensetzungen zur krebsbehandlung
JP2016531570A (ja) 2013-08-16 2016-10-13 ラナ セラピューティクス インコーポレイテッド ユークロマチン領域を標的とするオリゴヌクレオチド
CA2925107A1 (en) 2013-10-02 2015-04-09 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of the lect2 gene
LT3052628T (lt) 2013-10-04 2020-09-10 Alnylam Pharmaceuticals, Inc. Kompozicijos ir būdai alas1 geno raiškai nuslopinti
WO2015051283A1 (en) 2013-10-04 2015-04-09 Rana Therapeutics, Inc. Compositions and methods for treating amyotrophic lateral sclerosis
EP3683321B1 (de) 2013-10-21 2021-12-08 The General Hospital Corporation Verfahren im zusammenhang mit zirkulierenden tumorzellclustern und mit der behandlung von krebs
CN106061488B (zh) 2013-12-02 2021-04-09 菲奥医药公司 癌症的免疫治疗
SG10201804960RA (en) 2013-12-12 2018-07-30 Alnylam Pharmaceuticals Inc Complement component irna compositions and methods of use thereof
CN111729090A (zh) 2013-12-20 2020-10-02 通用医疗公司 与循环肿瘤细胞相关的方法和测定法
CN113057959B (zh) 2014-02-11 2024-07-16 阿尔尼拉姆医药品有限公司 己酮糖激酶（KHK）iRNA组合物及其使用方法
WO2015168108A2 (en) 2014-04-28 2015-11-05 Rxi Pharmaceuticals Corporation Methods for treating cancer using nucleic targeting mdm2 or mycn
TW201607559A (zh) 2014-05-12 2016-03-01 阿尼拉製藥公司 治療ｓｅｒｐｉｎｃ１相關疾患之方法和組成物
AU2015264038B2 (en) 2014-05-22 2021-02-11 Alnylam Pharmaceuticals, Inc. Angiotensinogen (AGT) iRNA compositions and methods of use thereof
EP3148564B1 (de) 2014-06-02 2020-01-08 Children's Medical Center Corporation Verfahren und zusammensetzungen zur immunmodulation
CN107106704A (zh) 2014-08-29 2017-08-29 儿童医疗中心有限公司 用于治疗癌症的方法和组合物
US10900039B2 (en) 2014-09-05 2021-01-26 Phio Pharmaceuticals Corp. Methods for treating aging and skin disorders using nucleic acids targeting Tyr or MMP1
WO2016040589A1 (en) 2014-09-12 2016-03-17 Alnylam Pharmaceuticals, Inc. Polynucleotide agents targeting complement component c5 and methods of use thereof
TW202503057A (zh) 2014-10-10 2025-01-16 美商艾爾妮蘭製藥公司 用於抑制hao1(羥酸氧化酶1(乙醇酸鹽氧化酶))基因表現的組合物及方法
WO2016061487A1 (en) 2014-10-17 2016-04-21 Alnylam Pharmaceuticals, Inc. Polynucleotide agents targeting aminolevulinic acid synthase-1 (alas1) and uses thereof
EP3212794B1 (de) 2014-10-30 2021-04-07 Genzyme Corporation Polynukleotidwirkstoffe mit abzielung auf serpinc1 (at3) und verfahren zur verwendung davon
WO2016070060A1 (en) 2014-10-30 2016-05-06 The General Hospital Corporation Methods for modulating atrx-dependent gene repression
KR102545316B1 (ko) 2014-11-10 2023-06-22 알닐람 파마슈티칼스 인코포레이티드 Ｂ형 간염 바이러스(ｈｂｖ) ｉｒｎａ 조성물 및 그의 이용 방법
JP2017535552A (ja) 2014-11-17 2017-11-30 アルナイラム ファーマシューティカルズ， インコーポレイテッドＡｌｎｙｌａｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． アポリポタンパク質Ｃ３（ＡＰＯＣ３）ｉＲＮＡ組成物およびその使用方法
CA2976445A1 (en) 2015-02-13 2016-08-18 Alnylam Pharmaceuticals, Inc. Patatin-like phospholipase domain containing 3 (pnpla3) irna compositions and methods of use thereof
US10758558B2 (en) 2015-02-13 2020-09-01 Translate Bio Ma, Inc. Hybrid oligonucleotides and uses thereof
EP3262181B1 (de) * 2015-02-23 2024-04-10 Ionis Pharmaceuticals, Inc. Verfahren zur flüssigphasendetritylierung von oligomeren verbindungen
WO2016149455A2 (en) 2015-03-17 2016-09-22 The General Hospital Corporation The rna interactome of polycomb repressive complex 1 (prc1)
AU2016243583B2 (en) 2015-03-27 2022-03-10 President And Fellows Of Harvard College Modified T cells and methods of making and using the same
US10745702B2 (en) 2015-04-08 2020-08-18 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of the LECT2 gene
MA42157A (fr) 2015-04-23 2018-02-28 Geron Corp Procédés de préparation de polynucléotides à l'aide de compositions de sel cationique multivalent
HK1251010A1 (zh) 2015-05-06 2019-01-18 Benitec IP Holdings Inc. 用於治疗乙型肝炎病毒(hbv)感染的试剂及用途
WO2016201301A1 (en) 2015-06-12 2016-12-15 Alnylam Pharmaceuticals, Inc. Complement component c5 irna compositions and methods of use thereof
EP3310918B1 (de) 2015-06-18 2020-08-05 Alnylam Pharmaceuticals, Inc. Gegen hydroxysäureoxidase (glycolat-oxidase, hao1) gerichtete polynukleotidwirkstoffe und verfahren zur verwendung davon
WO2016209862A1 (en) 2015-06-23 2016-12-29 Alnylam Pharmaceuticals, Inc. Glucokinase (gck) irna compositions and methods of use thereof
EP3862005A1 (de) 2015-07-06 2021-08-11 Phio Pharmaceuticals Corp. Gegen superoxid-dismutase 1 (sod1) gerichtete nukleinsäuremoleküle
US10808247B2 (en) 2015-07-06 2020-10-20 Phio Pharmaceuticals Corp. Methods for treating neurological disorders using a synergistic small molecule and nucleic acids therapeutic approach
WO2017011286A1 (en) 2015-07-10 2017-01-19 Alnylam Pharmaceuticals, Inc. Insulin-like growth factor binding protein, acid labile subunit (igfals) and insulin-like growth factor 1 (igf-1) irna compositions and methods of use thereof
CA2996873A1 (en) 2015-09-02 2017-03-09 Alnylam Pharmaceuticals, Inc. Programmed cell death 1 ligand 1 (pd-l1) irna compositions and methods of use thereof
WO2017070151A1 (en) 2015-10-19 2017-04-27 Rxi Pharmaceuticals Corporation Reduced size self-delivering nucleic acid compounds targeting long non-coding rna
TWI639614B (zh) 2015-11-06 2018-11-01 美商齊亞雋科學公司 核苷酸類似物
KR20180095843A (ko) 2015-12-07 2018-08-28 젠자임 코포레이션 Serpinc1-연관 장애의 치료를 위한 방법 및 조성물
NZ747314A (en) 2016-04-14 2022-07-29 Benitec Ip Holdings Inc Reagents for treatment of oculopharyngeal muscular dystrophy (opmd) and use thereof
WO2017184689A1 (en) 2016-04-19 2017-10-26 Alnylam Pharmaceuticals, Inc. High density lipoprotein binding protein (hdlbp/vigilin) irna compositions and methods of use thereof
EP3469083A1 (de) 2016-06-10 2019-04-17 Alnylam Pharmaceuticals, Inc. Gegen komplementkomponente c5 gerichtete irna-zusammensetzungen und verfahren zur verwendung davon zur behandlung von paroxysmaler nächtlicher hämoglobinurie (pnh)
AU2017354876A1 (en) * 2016-11-04 2019-06-20 Qiagen Sciences, Llc Thiol-containing cleave reagents and oxidative wash
WO2018112320A1 (en) 2016-12-16 2018-06-21 Alnylam Pharmaceuticals, Inc. Methods for treating or preventing ttr-associated diseases using transthyretin (ttr) irna compositions
KR20190135494A (ko) 2017-03-29 2019-12-06 로슈 이노베이션 센터 코펜하겐 에이/에스 입체한정된 포스포로티오에이트 올리고뉴클레오티드의 제조를 위한 직교 보호기
CA3059446A1 (en) 2017-04-18 2018-10-25 Alnylam Pharmaceuticals, Inc. Methods for the treatment of subjects having a hepatitis b virus (hbv) infection
US12544344B2 (en) 2017-04-19 2026-02-10 Phio Pharmaceuticals Corp. Topical delivery of nucleic acid compounds
TW202434265A (zh) 2017-07-10 2024-09-01 美商健贊公司 於患有血友病之個體中治療出血事件之方法及組成物
EP3652317A1 (de) 2017-07-13 2020-05-20 Alnylam Pharmaceuticals, Inc. Lactatdehydrogenase-a (ldha)-irna-zusammensetzungen und verfahren zu ihrer verwendung
SG11202002940QA (en) 2017-11-01 2020-04-29 Alnylam Pharmaceuticals Inc Complement component c3 irna compositions and methods of use thereof
US20200385719A1 (en) 2017-11-16 2020-12-10 Alnylam Pharmaceuticals, Inc. Kisspeptin 1 (kiss1) irna compositions and methods of use thereof
WO2019100039A1 (en) 2017-11-20 2019-05-23 Alnylam Pharmaceuticals, Inc. Serum amyloid p component (apcs) irna compositions and methods of use thereof
EP3728593A1 (de) 2017-12-18 2020-10-28 Alnylam Pharmaceuticals, Inc. Irna-zusammensetzungen der high-mobility-group box-1 (hmgb1) und verfahren zur verwendung davon
TWI851574B (zh) 2018-05-14 2024-08-11 美商阿尼拉製藥公司 血管收縮素原（ＡＧＴ）ｉＲＮＡ組成物及其使用方法
JP7625512B2 (ja) 2018-08-13 2025-02-03 アルナイラム ファーマシューティカルズ， インコーポレイテッド Ｂ型肝炎ウイルス（ＨＢＶ）ｄｓＲＮＡ物質組成物およびその使用方法
TW202020157A (zh) 2018-08-16 2020-06-01 美商艾爾妮蘭製藥公司 用於抑制lect2基因表現之組合物及方法
US20210332367A1 (en) 2018-09-18 2021-10-28 Alnylam Pharmaceuticals, Inc. KETOHEXOKINASE (KHK) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
US10913951B2 (en) 2018-10-31 2021-02-09 University of Pittsburgh—of the Commonwealth System of Higher Education Silencing of HNF4A-P2 isoforms with siRNA to improve hepatocyte function in liver failure
WO2020117706A1 (en) 2018-12-03 2020-06-11 Triplet Therapeutics, Inc. Methods for the treatment of trinucleotide repeat expansion disorders associated with mlh3 activity
AU2019406186A1 (en) 2018-12-20 2021-07-15 Praxis Precision Medicines, Inc. Compositions and methods for the treatment of KCNT1 related disorders
RS67553B1 (sr) 2018-12-20 2026-01-30 Humabs Biomed Sa Kombinovana hbv terapija
MX2021008628A (es) 2019-01-16 2021-11-17 Genzyme Corp Composiciones de arni para serpinc1 y metodos de uso de las mismas.
PH12021552870A1 (en) 2019-05-13 2022-03-21 Vir Biotechnology Inc Compositions and methods for treating hepatitis b virus (hbv) infection
EP4007812A1 (de) 2019-08-01 2022-06-08 Alnylam Pharmaceuticals, Inc. Irna-zusammensetzungen der serpinfamilie f element 2 (serpinf2) und verfahren zu deren verwendung
EP4007811A2 (de) 2019-08-01 2022-06-08 Alnylam Pharmaceuticals, Inc. Carboxypeptidase-b2(cpb2)-irna-zusammensetzungen und verfahren zur verwendung davon
EP4013870A1 (de) 2019-08-13 2022-06-22 Alnylam Pharmaceuticals, Inc. Irna-wirkstoffzusammensetzungen der kleinen ribosomalen proteinuntereinheit 25 (rps25) und verfahren zu ihrer verwendung
BR112022003860A2 (pt) 2019-09-03 2022-08-16 Alnylam Pharmaceuticals Inc Composições e métodos para inibir a expressão do gene lect2
JPWO2021045141A1 (de) * 2019-09-04 2021-03-11
US12503699B2 (en) 2019-10-04 2025-12-23 Alnylam Pharmaceuticals, Inc. Compositions and methods for silencing UGT1a1 gene expression
EP4045652A1 (de) 2019-10-18 2022-08-24 Alnylam Pharmaceuticals, Inc. Irna-zusammensetzungen eines elements der solute-carrier-familie und verwendungsverfahren dafür
WO2021081026A1 (en) 2019-10-22 2021-04-29 Alnylam Pharmaceuticals, Inc. Complement component c3 irna compositions and methods of use thereof
EP4051795A1 (de) 2019-11-01 2022-09-07 Alnylam Pharmaceuticals, Inc. Huntingtin (htt)-irna-wirkstoffzusammensetzungen und verfahren zu deren verwendung
US20230040920A1 (en) 2019-11-01 2023-02-09 Alnylam Pharmaceuticals, Inc. Compositions and methods for silencing dnajb1-prkaca fusion gene expression
BR112022009216A2 (pt) 2019-11-13 2022-08-02 Alnylam Pharmaceuticals Inc Métodos e composições para tratar um distúrbio associado a angiotensinogênio (agt)
US12565653B2 (en) 2019-11-22 2026-03-03 Alnylam Pharmaceuticals, Inc. ATAXIN3 (ATXN3) RNAi agent compositions and methods of use thereof
KR20220115995A (ko) 2019-12-13 2022-08-19 알닐람 파마슈티칼스 인코포레이티드 인간 염색체 ９ 개방 판독 프레임 72 (C9orf72) iRNA 제제 조성물 및 이의 사용 방법
WO2021126734A1 (en) 2019-12-16 2021-06-24 Alnylam Pharmaceuticals, Inc. Patatin-like phospholipase domain containing 3 (pnpla3) irna compositions and methods of use thereof
WO2021154941A1 (en) 2020-01-31 2021-08-05 Alnylam Pharmaceuticals, Inc. Complement component c5 irna compositions for use in the treatment of amyotrophic lateral sclerosis (als)
IL295445A (en) 2020-02-10 2022-10-01 Alnylam Pharmaceuticals Inc Preparations and methods for silencing vegf-a expression
JP7735288B2 (ja) 2020-02-18 2025-09-08 アルナイラム ファーマシューティカルズ， インコーポレイテッド アポリポタンパク質Ｃ３（ＡＰＯＣ３）ｉＲＮＡ組成物およびその使用法
EP4114947A1 (de) 2020-03-05 2023-01-11 Alnylam Pharmaceuticals, Inc. Komplementkomponenten-c3-irna-zusammensetzungen und verfahren zur verwendung davon zur behandlung oder prävention von mit komplementkomponenten-c3-assoziierten erkrankungen
BR112022017822A2 (pt) 2020-03-06 2022-11-08 Alnylam Pharmaceuticals Inc Composições de irna de cetoexocinase (khk) e métodos de uso das mesmas
EP4121534A1 (de) 2020-03-18 2023-01-25 Alnylam Pharmaceuticals, Inc. Zusammensetzungen und verfahren zur behandlung von patienten mit einer heterozygoten alaninglyoxylat-aminotransferase-genvariante (agxt)
TW202204615A (zh) 2020-03-26 2022-02-01 美商阿尼拉製藥公司 冠狀病毒ｉＲＮＡ組成物及其使用方法
US20230190785A1 (en) 2020-03-30 2023-06-22 Alnylam Pharmaceuticals, Inc. Compositions and methods for silencing dnajc15 gene expression
US12534731B2 (en) 2020-04-01 2026-01-27 Alnylam Pharmaceuticals, Inc. Alpha-2A adrenergic receptor (ADRA2A) iRNA agent compositions and methods of use thereof
KR20230008729A (ko) 2020-04-06 2023-01-16 알닐람 파마슈티칼스 인코포레이티드 Myoc 발현을 사일런싱하기 위한 조성물 및 방법
EP4133077A1 (de) 2020-04-07 2023-02-15 Alnylam Pharmaceuticals, Inc. Irna-zusammensetzungen mit transmembran-serinprotease 2 (tmprss2) und verfahren zur verwendung davon
JP2023521094A (ja) 2020-04-07 2023-05-23 アルナイラム ファーマシューティカルズ， インコーポレイテッド Ｓｃｎ９ａ発現をサイレンシングするための組成物および方法
EP4133076A1 (de) 2020-04-07 2023-02-15 Alnylam Pharmaceuticals, Inc. Irna-zusammensetzungen aus angiotensin-konvertierendem enzym 2 (ace2) und verfahren zur verwendung davon
IL297702A (en) 2020-04-27 2022-12-01 Alnylam Pharmaceuticals Inc Apolipoprotein e (apoe) irna agent compositions and methods of use thereof
JP2023523790A (ja) 2020-04-30 2023-06-07 アルナイラム ファーマシューティカルズ， インコーポレイテッド 補体因子Ｂ（ＣＦＢ）ｉＲＮＡ組成物およびその使用方法
WO2021231685A1 (en) 2020-05-15 2021-11-18 Korro Bio, Inc. Methods and compositions for the adar-mediated editing of transmembrane channel-like protein 1 (tmc1)
WO2021231680A1 (en) 2020-05-15 2021-11-18 Korro Bio, Inc. Methods and compositions for the adar-mediated editing of methyl-cpg binding protein 2 (mecp2)
EP4150087A1 (de) 2020-05-15 2023-03-22 Korro Bio, Inc. Verfahren und zusammensetzungen zur adar-vermittelten bearbeitung des gap-junction-proteins beta 2 (gjb2)
EP4150090A1 (de) 2020-05-15 2023-03-22 Korro Bio, Inc. Verfahren und zusammensetzungen zur adar-vermittelten bearbeitung von otoflin (otof)
WO2021231691A1 (en) 2020-05-15 2021-11-18 Korro Bio, Inc. Methods and compositions for the adar-mediated editing of retinoschisin 1 (rsi)
WO2021231673A1 (en) 2020-05-15 2021-11-18 Korro Bio, Inc. Methods and compositions for the adar-mediated editing of leucine rich repeat kinase 2 (lrrk2)
WO2021231698A1 (en) 2020-05-15 2021-11-18 Korro Bio, Inc. Methods and compositions for the adar-mediated editing of argininosuccinate lyase (asl)
WO2021231675A1 (en) 2020-05-15 2021-11-18 Korro Bio, Inc. Methods and compositions for the adar-mediated editing of argininosuccinate synthetase (ass1)
US20230183707A1 (en) 2020-05-21 2023-06-15 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting marc1 gene expression
MX2022014606A (es) 2020-05-22 2023-03-08 Wave Life Sciences Ltd Composiciones de oligonucleótidos bicatenarios y métodos relacionados con las mismas.
AR122534A1 (es) 2020-06-03 2022-09-21 Triplet Therapeutics Inc Métodos para el tratamiento de los trastornos de expansión por repetición de nucleótidos asociados con la actividad de msh3
EP4162050A1 (de) 2020-06-09 2023-04-12 Alnylam Pharmaceuticals, Inc. Rnai-zusammensetzungen und verfahren zur verwendung davon zur verabreichung durch inhalation
WO2021252649A2 (en) 2020-06-09 2021-12-16 Alnylam Pharmaceuticals, Inc. Sirna compositions and methods for silencing gpam (glycerol-3-phosphate acyltransferase 1, mitochondrial) expression
WO2021257782A1 (en) 2020-06-18 2021-12-23 Alnylam Pharmaceuticals, Inc. XANTHINE DEHYDROGENASE (XDH) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
PH12022553569A1 (en) 2020-06-24 2023-04-12 Humabs Biomed Sa Engineered hepatitis b virus neutralizing antibodies and uses thereof
WO2022066847A1 (en) 2020-09-24 2022-03-31 Alnylam Pharmaceuticals, Inc. Dipeptidyl peptidase 4 (dpp4) irna compositions and methods of use thereof
EP4225917A1 (de) 2020-10-05 2023-08-16 Alnylam Pharmaceuticals, Inc. G-protein-gekoppelter rezeptor-75 (gpr75)-irna-zusammensetzungen und verfahren zur verwendung davon
CA3198823A1 (en) 2020-10-21 2022-04-28 Alnylam Pharmaceuticals, Inc. Methods and compositions for treating primary hyperoxaluria
EP4232582A1 (de) 2020-10-23 2023-08-30 Alnylam Pharmaceuticals, Inc. Mucin-5b (muc5b)-irna-zusammensetzungen und verfahren zur verwendung davon
KR20230107625A (ko) 2020-11-13 2023-07-17 알닐람 파마슈티칼스 인코포레이티드 응고 인자 V(F5) iRNA 조성물 및 이의 사용 방법
TW202237150A (zh) 2020-12-01 2022-10-01 美商艾拉倫製藥股份有限公司 用於抑制ｈａｏ１（羥基酸氧化酶１（乙醇酸氧化酶））基因表現的方法及組成物
WO2022125490A1 (en) 2020-12-08 2022-06-16 Alnylam Pharmaceuticals, Inc. Coagulation factor x (f10) irna compositions and methods of use thereof
IL303886A (en) 2020-12-23 2023-08-01 Flagship Pioneering Inc Compositions of modified trems and uses thereof
EP4274896A1 (de) 2021-01-05 2023-11-15 Alnylam Pharmaceuticals, Inc. Komplementkomponente 9 (c9)-irna-zusammensetzungen und verfahren zur verwendung davon
EP4291654A2 (de) 2021-02-12 2023-12-20 Alnylam Pharmaceuticals, Inc. Superoxid-dismutase-1 (sod1)-irna-zusammensetzungen und verfahren zur verwendung davon zur behandlung oder vorbeugung von mit superoxid-dismutase 1 (sod1-) assoziierten neurodegenerativen erkrankungen
EP4298220A1 (de) 2021-02-25 2024-01-03 Alnylam Pharmaceuticals, Inc. Prionprotein (prnp)-irna-zusammensetzungen und verfahren zur verwendung davon
AU2022226098A1 (en) 2021-02-26 2023-08-24 Alnylam Pharmaceuticals, Inc. KETOHEXOKINASE (KHK) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
JP2024508896A (ja) 2021-03-04 2024-02-28 アルナイラム ファーマシューティカルズ， インコーポレイテッド アンジオポエチン様３（ＡＮＧＰＴＬ３）ｉＲＮＡ組成物およびその使用方法
WO2022192519A1 (en) 2021-03-12 2022-09-15 Alnylam Pharmaceuticals, Inc. Glycogen synthase kinase 3 alpha (gsk3a) irna compositions and methods of use thereof
EP4314296A2 (de) 2021-03-29 2024-02-07 Alnylam Pharmaceuticals, Inc. Huntingtin (htt)-irna-wirkstoffzusammensetzungen und verfahren zur verwendung davon
EP4314293A1 (de) 2021-04-01 2024-02-07 Alnylam Pharmaceuticals, Inc. Prolindehydrogenase 2 (prodh2)-irna-zusammensetzungen und verfahren zur verwendung davon
EP4330392A1 (de) 2021-04-26 2024-03-06 Alnylam Pharmaceuticals, Inc. Transmembranprotease, serin 6 (tmprss6)-irna-zusammensetzungen und verfahren zur verwendung davon
WO2022232343A1 (en) 2021-04-29 2022-11-03 Alnylam Pharmaceuticals, Inc. Signal transducer and activator of transcription factor 6 (stat6) irna compositions and methods of use thereof
EP4341401A1 (de) 2021-05-18 2024-03-27 Alnylam Pharmaceuticals, Inc. Natriumglucose-cotransporter-2-(sglt2)-irna-zusammensetzungen und verfahren zur verwendung davon
EP4341405A1 (de) 2021-05-20 2024-03-27 Korro Bio, Inc. Verfahren und zusammensetzungen für adar-vermittelte bearbeitung
WO2022256283A2 (en) 2021-06-01 2022-12-08 Korro Bio, Inc. Methods for restoring protein function using adar
EP4347823A1 (de) 2021-06-02 2024-04-10 Alnylam Pharmaceuticals, Inc. Patin-ähnliche phospholipasedomäne mit 3 (pnpla3)-irna-zusammensetzungen und verfahren zur verwendung davon
EP4347822A2 (de) 2021-06-04 2024-04-10 Alnylam Pharmaceuticals, Inc. Irna-wirkstoffzusammensetzungen mit offenem leserahmen 72 (c9orf72) auf menschlichem chromosom 9 und verfahren zur verwendung davon
AR126070A1 (es) 2021-06-08 2023-09-06 Alnylam Pharmaceuticals Inc Composiciones y métodos para tratar o prevenir la enfermedad de stargardt y/o trastornos asociados con la proteína transportadora de retinol 4 (rbp4)
EP4363574A1 (de) 2021-06-29 2024-05-08 Korro Bio, Inc. Verfahren und zusammensetzungen für adar-vermittelte bearbeitung
US20230194709A9 (en) 2021-06-29 2023-06-22 Seagate Technology Llc Range information detection using coherent pulse sets with selected waveform characteristics
AU2022303164A1 (en) 2021-06-30 2024-01-18 Alnylam Pharmaceuticals, Inc. Methods and compositions for treating an angiotensinogen- (agt-) associated disorder
WO2023003805A1 (en) 2021-07-19 2023-01-26 Alnylam Pharmaceuticals, Inc. Methods and compositions for treating subjects having or at risk of developing a non-primary hyperoxaluria disease or disorder
AU2022316139A1 (en) 2021-07-23 2024-01-18 Alnylam Pharmaceuticals, Inc. Beta-catenin (ctnnb1) irna compositions and methods of use thereof
WO2023009687A1 (en) 2021-07-29 2023-02-02 Alnylam Pharmaceuticals, Inc. 3-hydroxy-3-methylglutaryl-coa reductase (hmgcr) irna compositions and methods of use thereof
CA3227852A1 (en) 2021-08-03 2023-02-09 Alnylam Pharmaceuticals, Inc. Transthyretin (ttr) irna compositions and methods of use thereof
EP4381071A1 (de) 2021-08-04 2024-06-12 Alnylam Pharmaceuticals, Inc. Irna-zusammensetzungen und verfahren zur ausschaltung von angiotensinogen (att)
CN118076737A (zh) 2021-08-13 2024-05-24 阿尔尼拉姆医药品有限公司 因子XII（F12）iRNA组合物及其使用方法
JP2024538859A (ja) 2021-08-31 2024-10-24 アルナイラム ファーマシューティカルズ， インコーポレイテッド 細胞死誘導ＤＦＦＡ様エフェクターＢ（ＣＩＤＥＢ）ｉＲＮＡ組成物およびその使用方法
JP2024535850A (ja) 2021-09-17 2024-10-02 アルナイラム ファーマシューティカルズ， インコーポレイテッド 補体成分（Ｃ３）をサイレンシングするためのｉＲＮＡ組成物および方法
AU2022345881A1 (en) 2021-09-20 2024-03-21 Alnylam Pharmaceuticals, Inc. Inhibin subunit beta e (inhbe) modulator compositions and methods of use thereof
TW202328449A (zh) 2021-09-24 2023-07-16 美商艾拉倫製藥公司 微管相關蛋白ＴＡＵ（ＭＡＰＴ）ｉＲＮＡ試劑組合物及其使用方法
WO2023069603A1 (en) 2021-10-22 2023-04-27 Korro Bio, Inc. Methods and compositions for disrupting nrf2-keap1 protein interaction by adar mediated rna editing
EP4423272A2 (de) 2021-10-29 2024-09-04 Alnylam Pharmaceuticals, Inc. Huntingtin (htt)-irna-wirkstoffzusammensetzungen und verfahren zur verwendung davon
CN118302525A (zh) 2021-10-29 2024-07-05 阿尔尼拉姆医药品有限公司 补体因子B（CFB）iRNA组合物及其使用方法
WO2023141314A2 (en) 2022-01-24 2023-07-27 Alnylam Pharmaceuticals, Inc. Heparin sulfate biosynthesis pathway enzyme irna agent compositions and methods of use thereof
CN114591387A (zh) * 2022-03-21 2022-06-07 通用生物(滁州)有限公司 一种药用核酸合成后的胺洗工艺
WO2024039776A2 (en) 2022-08-18 2024-02-22 Alnylam Pharmaceuticals, Inc. Universal non-targeting sirna compositions and methods of use thereof
EP4569113A1 (de) 2022-09-15 2025-06-18 Regeneron Pharmaceuticals, Inc. 17b-hydroxysteroiddehydrogenase-typ-13 (hsd17b13)-irna-zusammensetzungen und verfahren zu ihrer verwendung
GB2626789A (en) * 2023-02-03 2024-08-07 Exactmer Ltd Deprotection processes and cation scavengers for use in the same
TW202449152A (zh) 2023-02-09 2024-12-16 美商艾拉倫製藥股份有限公司 Ｒｅｖｅｒｓｉｒ分子及其使用方法
WO2024220746A2 (en) 2023-04-21 2024-10-24 Flagship Pioneering Innovations Vii, Llc Rnai agents targeting fatty acid synthase and related methods
WO2025015335A1 (en) 2023-07-13 2025-01-16 Korro Bio, Inc. Rna-editing oligonucleotides and uses thereof
AU2024299328A1 (en) 2023-07-21 2026-01-22 Marrow Therapeutics, Inc. Hematopoietic cell targeting conjugates and related methods
KR20260044217A (ko) 2023-07-25 2026-04-01 플래그쉽 파이어니어링 이노베이션스 Vii, 엘엘씨 Cas 엔도뉴클레아제 및 관련 방법
WO2025024493A1 (en) 2023-07-25 2025-01-30 Flagship Pioneering Innovations Vii, Llc Cas endonucleases and related methods
KR20260049597A (ko) 2023-08-04 2026-04-14 알닐람 파마슈티칼스 인코포레이티드 Ctnnb1-관련 질환을 치료하기 위한 방법 및 조성물
WO2025072331A1 (en) 2023-09-26 2025-04-03 Flagship Pioneering Innovations Vii, Llc Cas nucleases and related methods
WO2025072699A1 (en) 2023-09-27 2025-04-03 Judo Bio, Inc. Aminoglycosides for delivery of agents to the kidney
WO2025072672A2 (en) 2023-09-27 2025-04-03 Judo Bio, Inc. Slc6a19-targeting modulatory nucleic acid agents
WO2025072713A1 (en) 2023-09-27 2025-04-03 Judo Bio, Inc. Polymyxins for delivery of agents to the kidney
WO2025076031A2 (en) 2023-10-03 2025-04-10 Alnylam Pharmaceuticals, Inc. Peritoneal macrophages comprising a nanoparticle encapsulating a nucleic acid molecule and methods of use thereof
WO2025117877A2 (en) 2023-12-01 2025-06-05 Flagship Pioneering Innovations Vii, Llc Cas nucleases and related methods
WO2025128799A1 (en) 2023-12-12 2025-06-19 Korro Bio, Inc. Double-stranded rna-editing oligonucleotides and uses thereof
WO2025178854A2 (en) 2024-02-19 2025-08-28 Flagship Pioneering Innovations Vii, Llc Rnai agents targeting cideb and related methods
WO2025199231A2 (en) 2024-03-20 2025-09-25 Vertex Pharmaceuticals Incorporated Mucin-5b (muc5b) targeted sirna and antisense oligonucleotides and methods of use thereof
WO2025217275A2 (en) 2024-04-10 2025-10-16 Flagship Pioneering Innovations Vii, Llc Immune cell targeted compositions and related methods
WO2025259743A1 (en) 2024-06-12 2025-12-18 Alnylam Pharmaceuticals, Inc. Dual conjugate compounds for extrahepatic delivery
WO2025259747A2 (en) 2024-06-12 2025-12-18 Alnylam Pharmaceuticals, Inc. Dystrophy myotonic protein kinase (dmpk) irna compositions and methods of use thereof
WO2026055461A1 (en) 2024-09-05 2026-03-12 Aperture Therapeutics, Inc. Antibody oligonucleotide conjugates comprising an antisense polynucleotide agent conjugated to a cd33 antibody and methods of use thereof

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3687808A (en) 1969-08-14 1972-08-29 Univ Leland Stanford Junior Synthetic polynucleotides
US4500707A (en) 1980-02-29 1985-02-19 University Patents, Inc. Nucleosides useful in the preparation of polynucleotides
US5132418A (en) 1980-02-29 1992-07-21 University Patents, Inc. Process for preparing polynucleotides
US4458066A (en) 1980-02-29 1984-07-03 University Patents, Inc. Process for preparing polynucleotides
US4415732A (en) 1981-03-27 1983-11-15 University Patents, Inc. Phosphoramidite compounds and processes
US4668777A (en) 1981-03-27 1987-05-26 University Patents, Inc. Phosphoramidite nucleoside compounds
US4973679A (en) 1981-03-27 1990-11-27 University Patents, Inc. Process for oligonucleo tide synthesis using phosphormidite intermediates
US4426517A (en) * 1981-08-24 1984-01-17 Eli Lilly And Company Process for de-cyanoethylating blocked nucleotides
US4417046A (en) * 1981-08-24 1983-11-22 Eli Lilly And Company Process for isolating oligonucleotide product from a coupling reaction mixture
US4396740A (en) * 1982-05-03 1983-08-02 Borg-Warner Chemicals, Inc. Scavenging of residual acrylonitrile monomer in ABS latex
FR2540122B1 (fr) * 1983-01-27 1985-11-29 Centre Nat Rech Scient Nouveaux composes comportant une sequence d'oligonucleotide liee a un agent d'intercalation, leur procede de synthese et leur application
DE3329892A1 (de) 1983-08-18 1985-03-07 Köster, Hubert, Prof. Dr., 2000 Hamburg Verfahren zur herstellung von oligonucleotiden
USRE34069E (en) 1983-08-18 1992-09-15 Biosyntech Gmbh Process for the preparation of oligonucleotides
US5362866A (en) 1983-09-02 1994-11-08 Molecular Biosystems, Inc. Oligonucleotide polymeric support system with an oxidation cleavable link
US4672110A (en) 1983-11-29 1987-06-09 Northwestern University Method of deprotecting polynucleotide trimethylethyl phosphotriesters
JPS6242997A (ja) * 1985-08-19 1987-02-24 Akira Kaji ヌクレオシドアルキルホスホネイトの製造方法
JPS6243997A (ja) * 1985-08-22 1987-02-25 Matsushita Electric Ind Co Ltd 映像信号処理装置
JP2696529B2 (ja) 1988-04-26 1998-01-14 東和化成工業株式会社 粉末マルトース及び粉末マルチトールの製造法
US5212295A (en) 1990-01-11 1993-05-18 Isis Pharmaceuticals Monomers for preparation of oligonucleotides having chiral phosphorus linkages
SE9003743D0 (sv) * 1990-11-26 1990-11-26 Pharmacia Ab Method and means for oligonucleotide synthesis
US5210264A (en) 1992-01-10 1993-05-11 Isis Pharmaceuticals, Inc. S-(2,4-dichlorobenzyl)-β-cyanoethyl phosphorothioate diester
US5948898A (en) * 1992-03-16 1999-09-07 Isis Pharmaceuticals, Inc. Methoxyethoxy oligonucleotides for modulation of protein kinase C expression
US5804683A (en) 1992-05-14 1998-09-08 Ribozyme Pharmaceuticals, Inc. Deprotection of RNA with alkylamine
US5977343A (en) * 1992-05-14 1999-11-02 Ribozyme Pharmaceuticals, Inc. Synthesis, deprotection, analysis and purification of RNA and ribozymes
US5686599A (en) * 1992-05-14 1997-11-11 Ribozyme Pharmaceuticals, Inc. Synthesis, deprotection, analysis and purification of RNA and ribozymes
US5629150A (en) * 1993-08-30 1997-05-13 Isis Pharmaceuticals, Inc. Methods for characterizing phosphorothioate oligonucleotides
US5514789A (en) * 1994-04-21 1996-05-07 Barrskogen, Inc. Recovery of oligonucleotides by gas phase cleavage
US5510476A (en) * 1994-07-07 1996-04-23 Isis Pharmaceuticals, Inc. Carbocation scavenging during oligonucleotide synthesis
US6166197A (en) 1995-03-06 2000-12-26 Isis Pharmaceuticals, Inc. Oligomeric compounds having pyrimidine nucleotide (S) with 2'and 5 substitutions
US5808039A (en) * 1995-10-18 1998-09-15 Beckman Instruments, Inc. 2'-OMe CAC phosphoramidite and methods for preparation and use thereof
US5869696A (en) * 1996-04-22 1999-02-09 Beckman Instruments, Inc. Universal solid supports and methods for their use
DE19627898A1 (de) 1996-07-11 1998-01-15 Hoechst Ag Festphasensynthese von Oligonucleotiden
US5750672A (en) * 1996-11-22 1998-05-12 Barrskogen, Inc. Anhydrous amine cleavage of oligonucleotides
US6172209B1 (en) 1997-02-14 2001-01-09 Isis Pharmaceuticals Inc. Aminooxy-modified oligonucleotides and methods for making same
JP4538106B2 (ja) * 1997-07-16 2010-09-08 ザ ガバメント オブ ザ ユナイテッド ステイツ オブ アメリカ，リプリゼンテッド バイ ザ セクレタリー，デパートメント オブ ヘルス アンド ヒューマン サービス 食品品質指示薬装置
US6054576A (en) * 1997-10-02 2000-04-25 Ribozyme Pharmaceuticals, Inc. Deprotection of RNA
US6271358B1 (en) 1998-07-27 2001-08-07 Isis Pharmaceuticals, Inc. RNA targeted 2′-modified oligonucleotides that are conformationally preorganized
US6465628B1 (en) * 1999-02-04 2002-10-15 Isis Pharmaceuticals, Inc. Process for the synthesis of oligomeric compounds
US6887990B1 (en) 1999-02-05 2005-05-03 Amersham Biosciences Corp Method for deprotecting oligonucleotides
MXPA02012216A (es) * 2000-06-12 2004-08-19 Avecia Biotechnology Inc Desproteccion de oligonucleotidos sinteticos usando un secuestrante de acrilonitrilo.
ATE312841T1 (de) * 2001-03-08 2005-12-15 Applera Corp Verfahren zum entschützen von oligonukleotide

Also Published As

Publication number Publication date
EP1028124A2 (de) 2000-08-16
US20070265435A1 (en) 2007-11-15
US20050137391A1 (en) 2005-06-23
US20050182251A1 (en) 2005-08-18
JP2000226399A (ja) 2000-08-15
DE69937439D1 (de) 2007-12-13
ES2296372T5 (es) 2016-05-26
US6858715B2 (en) 2005-02-22
US7199236B2 (en) 2007-04-03
US7186822B2 (en) 2007-03-06
US20050137390A1 (en) 2005-06-23
US7041816B2 (en) 2006-05-09
DE69937439T3 (de) 2016-06-09
US20040219577A1 (en) 2004-11-04
US6465628B1 (en) 2002-10-15
EP1028124B2 (de) 2016-01-27
EP1028124B1 (de) 2007-10-31
ES2296372T3 (es) 2008-04-16
US7227016B2 (en) 2007-06-05
DE69937439T2 (de) 2008-08-21
EP1028124A3 (de) 2000-09-06
US20030088088A1 (en) 2003-05-08

Similar Documents

Publication Publication Date Title
ATE377019T1 (de) Verbesserter entschützungsmethode für die synthese von oligomerverbindungen
DE60104726D1 (de) Verfahren zur Behandlung von faserigen Substraten mit alkylierten fluorochemikalischen Oligomeren, sowie damit behandelte faserige Substrate
DE69840748D1 (de) Verfahren zur zubereitung von antisense oligonukleotiden
BR9610908A (pt) Processos para preparação de precursores de cadeia lateral de taxanos de taxanos e de baccatine iii e compostos precursores de cadeias laterais de taxanos
WO2001081308A3 (en) Aminopiperidines for use as glyt-1 inhibitors
BR9815441B1 (pt) processo aperfeiçoado para decomposição de um hidroperóxido.
EP1023310A4 (de) Synthese von sulfurierten oligonukleotiden
DE69733150D1 (de) Verfahren zur herstellung von nukleotiden oder oligonukleotiden phosphoramitiden
DE60124289D1 (de) Verfahren zur herstellung von 21-hydroxy-6,19-oxidoprogesteron (21oh-6op)
ATE268996T1 (de) Verbessertes formverfahren für konfektprodukte
DE69731112D1 (de) Verfahren zur synthese von phosphorothioat-oligonukelotiden
NO177308C (no) Analogifremgangsmåte ved fremstilling av anti-tumorforbindelser
BR9808664A (pt) Processo para preparar eprosartan
IT1303265B1 (it) Platorello o semiplatorello per macchine circolari monocilindricheper maglieria o calzetteria, particolarmente per la produzione di
BR0013094B1 (pt) processo para a preparação de compostos 1,3-dicarbonìlicos acilados.
ZA995559B (en) Improved process for the production of an n-acyl derivative of O,S-dialkyl phosphoroamidothioate.
EP0648844A3 (de) Verfahren zur Selektion der Träger von abnormalen genetischen Basissequenzen.
DE59712270D1 (de) Verfahren zur kombination von paralleler oligonukleotidsynthese und darstellung von oligomer-chips
ATE239047T1 (de) Polymere antitumormittel
ID18620A (id) Proses-proses untuk memproduksi 1,6-heksanadiol
GR3035254T3 (en) Geminal cationic surfactants of the type n alpha n omega bis(n alpha-acyl-arginin) alpha, omega diamino alkyl dichlorohydrates as antimicrobial agents
DE60218236D1 (de) Herstellung von aromatischen Phosphiten
HUT62255A (en) Process for producing radioprotective polyamine phenols
MX9603335A (es) Descomposicion termica de acidos naftenicos.
TR199900672T2 (xx) Benzotiofenlerin sentezi i�in i�lem.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties